Reference

Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation

Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. Ochiai, Takenori; Gunji, Y.; Nagata, M.; Asano, T.; Isono, K. (Sch. Med.Several reagents with their cas registry numbers 128794-94-5 and 104987-11-3 are used here., Chiba Univ., Chiba 280, Japan). Transplant. Proc., 23(6), 2718-19 (English) 1991. CODEN: TRPPA8. ISSN: 0041-1345. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The combination treatment with FK 506 and rapamycin or RS 61443 in renal allotransplantation in dogs prolonged recipient survival times and lowered the frequency of vasculitis. .

Mycophenolate mofetil: a unique immunosuppressive agent

Mycophenolate mofetil: a unique immunosuppressive agent. Hood, Kerri A.; Zarembski, Dawn G. (Clinical Specialist, Solid-Organ Transplant, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, USA). American Journal of Health-System Pharmacy, 54(3), 285-294 (English) 1997 American Society of Health-System Pharmacists. CODEN: AHSPEK. ISSN: 1079-2082. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review with 43 refs. The mechanism of action, pharmacokinetics, clin. efficacy, adverse effects, and dosage and administration of mycophenolate mofetil are reviewed. Mycophenolate mofetil is used to prevent or treat allograft rejection after solid-organ transplantation. A prodrug, mycophenolate mofetil is rapidly hydrolyzed to mycophenolic acid after oral administration. Mycophenolic acid inhibits denovo purine synthesis, resulting in antiproliferative effects on T and B lymphocytes. The abs. bioavailability of mycophenolic acid is 94% for oral administration; the max. plasma concn. occurs after two hours. Mycophenolic acid undergoes hepatic glucuronidation to an inactive salt that is renally excreted. Clin. trials of mycophenolate mofetil in renal transplant patients suggest that the drug is effective for the prevention of acute rejection and as rescue therapy. Clin. data on mycophenolate mofetil therapy in liver transplant patients are too limited to permit conclusions. Clin. trials of the drug for primary immunosuppression in heart transplant patients have not been conducted, but studies of this agent as rescue therapy suggest efficacy. Mycophenolic acid has proved useful for long-term management of psoriasis. The most common adverse effects of mycophenolate mofetil are gastrointestinal. Nephrotoxicity and overt hepatotoxicity have not been reported, but the drug may be linked to bone marrow suppression and certain malignancies. Mycophenolate mofetil is available as a 250-mg capsule for oral use. The recommended initial dosage is 1 g twice daily. Mycophenolate mofetil appears to be a useful addn. to the armamentarium of immunosuppressive drugs, particularly for kidney transplant patients, but more study is needed to clarify its role.Except for chemicals metioned above, 128794-94-5 is also used. .